News coverage about Biocept (NASDAQ:BIOC) has trended positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biocept earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.4962048631997 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- 5 Medtech Stocks to Steer Clear of Amid Political Chaos (finance.yahoo.com)
- Biocept, Inc. (BIOC) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Biocept, Inc. (BIOC) has a value of $1.35 per share While Endocyte, Inc. (ECYT) is stand at $1.38 – Stocks Gallery (stocksgallery.com)
- Circulating Tumor Cell Market 2017 -Current Trends and Development & Potential of Market CAGR 13.8% forecasted period 2017-2023. (empowerednews.net)
- Trading summary on Biocept, Inc. (BIOC) – Wall Street Morning (wallstreetmorning.com)
Shares of Biocept (NASDAQ BIOC) traded down 1.56% during trading on Tuesday, hitting $1.26. The stock had a trading volume of 202,076 shares. The stock’s 50 day moving average is $1.28 and its 200-day moving average is $1.57. The company’s market cap is $38.12 million. Biocept has a 12-month low of $0.74 and a 12-month high of $3.39.
Biocept (NASDAQ:BIOC) last announced its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01). The business had revenue of $1.28 million during the quarter, compared to analysts’ expectations of $1.23 million. Biocept had a negative net margin of 359.48% and a negative return on equity of 550.35%. Analysts forecast that Biocept will post ($0.79) earnings per share for the current year.
Several brokerages have recently commented on BIOC. ValuEngine lowered Biocept from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 8th. Westpark Capital reaffirmed an “outperform” rating on shares of Biocept in a research note on Thursday, August 3rd. Finally, Zacks Investment Research lowered Biocept from a “buy” rating to a “hold” rating in a research note on Thursday, June 1st. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $2.25.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.